Baxter (BAX) Tops Q1 EPS by 4c; offers outlook

Baxter (NYSE: BAX) reported Q1 EPS of $0.65, $0.04 better than the analyst estimate of $0.61. Revenue for the quarter came in at $3.59 million versus the consensus estimate of $3.55 billion.

GUIDANCE:

Baxter sees FY2024 EPS of $2.88-$2.98, versus the consensus of $2.90. For full-year 2024: Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis

Baxter sees Q2 2024 EPS of $0.65-$0.67, versus the consensus of $0.67. For second-quarter 2024: The company expects sales growth of approximately 1% on a reported basis and 2% to 3% on a constant currency basis

For earnings history and earnings-related data on Baxter (BAX) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion
• Morgan Stanley Resumes Bath & Body Works Inc. (BBWI) at Equalweight